Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
22,7 NOK | +0,44% | -3,40% | -2,58% |
24/04 | Vistin Pharma ASA publie ses résultats pour le premier trimestre clos le 31 mars 2024 | CI |
24/04 | Transcript : Vistin Pharma ASA, Q1 2024 Earnings Call, Apr 24, 2024 |
Métier
Nombre d'employés: 75
Ventes par activité
NOK en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Pharmaceuticals
100,0
%
| 288 | 100,0 % | 435 | 100,0 % | +51,35% |
Ventes par région
NOK en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Europe
77,8
%
| 196 | 68,1 % | 339 | 77,8 % | +72,91% |
Africa
15,1
%
| 37 | 13,0 % | 66 | 15,1 % | +75,29% |
Asia
6,7
%
| 20 | 6,9 % | 29 | 6,7 % | +48,11% |
North and South America
0,3
%
| 34 | 12,0 % | 2 | 0,3 % | -95,63% |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Chief Executive Officer | - | 01/03/20 | |
Director of Finance/CFO | - | 02/03/20 | |
Eivind Egeli
CTO | Chief Tech/Sci/R&D Officer | - | 01/06/15 |
Vegard Heggem
PRN | Corporate Officer/Principal | - | 01/06/15 |
Sabrina Berge
PRN | Corporate Officer/Principal | - | 01/06/15 |
General Counsel | - | 01/03/15 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Chairman | 76 | 01/06/20 | |
Director/Board Member | 62 | 06/03/15 | |
Director/Board Member | 60 | - | |
Bettina Banoun
BRD | Director/Board Member | 52 | 08/05/18 |
Åse Musum
BRD | Director/Board Member | - | 01/06/15 |
Director/Board Member | - | 04/05/20 | |
Director/Board Member | - | 01/01/17 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 44 344 592 | 20 062 899 ( 45,24 %) | 0 | 45,24 % |
Coordonnées société
Sociétés du groupe
Nom | Catégorie et Secteur |
---|---|
Vistin Trading AS
Vistin Trading AS Finance/Rental/LeasingFinance Part of Vistin Pharma ASA, Vistin Trading AS offers trade in financial instruments and other investments. The private company is based in Oslo, Norway. |
Finance/Rental/Leasing
|
Vistin Pharma AS
Vistin Pharma AS Pharmaceuticals: MajorHealth Technology Part of Vistin Pharma ASA, Vistin Pharma is a leading European metformin producer supplying to international pharmaceutical companies. The private company is located in Norway. Metformin is a standard first-line treatment for type 2 diabetes. The Norwegian company believes in balancing business growth with environmental sustainability, social responsibility, and ethical business practices. |
Pharmaceuticals: Major
|
Secteur
Ventes par région
Varia. 1 janv. | Capi. | |
---|---|---|
-2,58% | 92,2 M | |
+20,83% | 43,57 Md | |
+20,70% | 22,7 Md | |
+16,41% | 14,32 Md | |
+11,11% | 13,42 Md | |
+45,91% | 11,83 Md | |
-8,84% | 6,98 Md | |
-0,05% | 6,79 Md | |
-8,87% | 5,73 Md | |
+12,41% | 5,51 Md |
- Bourse
- Actions
- Action VISTN
- Société Vistin Pharma ASA